This is an aggregated industry headline. Read the full story at Endpoints News →
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted "pan-RAS" drug doubled the survival time for patients whose pancreatic cancer has returned or stopped ...
By Endpoints News
· Apr 17, 2026
· via Endpoints News
Image: Endpoints News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w…
The WeekFierceBiotech ↗
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Thera…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…